Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CKPTNASDAQ:MGNXNASDAQ:ORICNASDAQ:ORKA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCKPTCheckpoint Therapeutics$4.10+0.2%$3.70$1.38▼$4.50$343.43M1.211.24 million shs1.26 million shsMGNXMacroGenics$1.71-4.5%$1.83$0.99▼$16.44$107.88M2.231.14 million shs836,380 shsORICORIC Pharmaceuticals$5.10-1.7%$6.39$3.90▼$14.67$362.24M1.38635,470 shs362,897 shsORKAOruka Therapeutics$10.09-3.9%$10.04$5.49▼$31.13$377.78M0.47237,548 shs156,791 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCKPTCheckpoint Therapeutics0.00%+1.49%+1.49%+42.86%+186.71%MGNXMacroGenics0.00%+35.71%+35.71%-46.39%-88.26%ORICORIC Pharmaceuticals0.00%+6.92%-16.94%-52.91%-36.80%ORKAOruka Therapeutics0.00%+9.50%-19.28%-11.80%+1,008,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCKPTCheckpoint Therapeutics2.4035 of 5 stars1.24.00.04.22.70.80.0MGNXMacroGenics3.8687 of 5 stars3.22.00.04.42.22.50.6ORICORIC Pharmaceuticals3.9811 of 5 stars3.52.00.04.32.81.70.6ORKAOruka Therapeutics3.0828 of 5 stars3.60.00.00.02.64.20.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCKPTCheckpoint Therapeutics 2.33Hold$4.335.69% UpsideMGNXMacroGenics 2.36Hold$7.38331.29% UpsideORICORIC Pharmaceuticals 3.00Buy$18.86269.75% UpsideORKAOruka Therapeutics 3.22Buy$39.86295.02% UpsideCurrent Analyst Ratings BreakdownLatest MGNX, ORKA, ORIC, and CKPT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/31/2025CKPTCheckpoint TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.80 ➝ $4.803/25/2025MGNXMacroGenicsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$4.00 ➝ $2.003/20/2025ORICORIC PharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$20.003/11/2025CKPTCheckpoint TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$4.103/10/2025CKPTCheckpoint TherapeuticsLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold$7.00 ➝ $4.103/10/2025CKPTCheckpoint TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $4.803/7/2025ORKAOruka TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$40.002/26/2025ORICORIC PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$21.00 ➝ $22.002/26/2025ORICORIC PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy2/21/2025ORICORIC PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$21.00 ➝ $21.002/11/2025ORICORIC PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$21.00 ➝ $21.00(Data available from 4/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCKPTCheckpoint Therapeutics$41K8,376.40N/AN/A($0.47) per share-8.72MGNXMacroGenics$148.34M0.73N/AN/A$2.46 per share0.70ORICORIC PharmaceuticalsN/AN/AN/AN/A$3.42 per shareN/AORKAOruka TherapeuticsN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCKPTCheckpoint Therapeutics-$51.85M-$1.43N/A∞N/AN/AN/A-659.07%5/9/2025 (Estimated)MGNXMacroGenics-$9.06M-$1.08N/AN/AN/A-69.07%-89.42%-38.57%5/8/2025 (Estimated)ORICORIC Pharmaceuticals-$100.70M-$1.82N/AN/AN/AN/A-44.54%-40.72%5/5/2025 (Estimated)ORKAOruka Therapeutics-$5.34M-$5.79N/AN/AN/AN/A-24.96%-21.22%N/ALatest MGNX, ORKA, ORIC, and CKPT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2025Q1 2025CKPTCheckpoint Therapeutics-$0.10N/AN/AN/AN/AN/A5/8/2025Q1 2025MGNXMacroGenics-$0.61N/AN/AN/A$9.59 millionN/A5/5/2025Q1 2025ORICORIC Pharmaceuticals-$0.52N/AN/AN/AN/AN/A3/28/2025Q4 2024CKPTCheckpoint Therapeutics-$0.22-$0.69-$0.47-$0.69N/A$0.04 million3/20/2025Q4 2024MGNXMacroGenics-$0.23-$0.25-$0.02-$0.25$34.17 million$49.40 million3/6/2025Q4 2024ORKAOruka Therapeutics-$0.68-$0.49+$0.19-$0.49N/AN/A2/18/2025Q4 2024ORICORIC Pharmaceuticals-$0.52-$0.51+$0.01-$0.51N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCKPTCheckpoint TherapeuticsN/AN/AN/AN/AN/AMGNXMacroGenicsN/AN/AN/AN/AN/AORICORIC PharmaceuticalsN/AN/AN/AN/AN/AORKAOruka TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCKPTCheckpoint TherapeuticsN/A0.290.29MGNXMacroGenicsN/A3.753.69ORICORIC PharmaceuticalsN/A10.5613.15ORKAOruka TherapeuticsN/A22.8922.89Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCKPTCheckpoint Therapeutics22.00%MGNXMacroGenics96.89%ORICORIC Pharmaceuticals95.05%ORKAOruka Therapeutics56.44%Insider OwnershipCompanyInsider OwnershipCKPTCheckpoint Therapeutics2.10%MGNXMacroGenics13.00%ORICORIC Pharmaceuticals5.55%ORKAOruka Therapeutics22.67%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCKPTCheckpoint Therapeutics1083.76 million47.81 millionOptionableMGNXMacroGenics43063.09 million55.67 millionOptionableORICORIC Pharmaceuticals8071.03 million67.09 millionOptionableORKAOruka TherapeuticsN/A37.44 million27.07 millionN/AMGNX, ORKA, ORIC, and CKPT HeadlinesRecent News About These CompaniesOruka Therapeutics, Inc. (NASDAQ:ORKA) Shares Bought by SR One Capital Management LPApril 19, 2025 | marketbeat.comOruka Therapeutics (ORKA) Projected to Post Quarterly Earnings on ThursdayApril 18, 2025 | marketbeat.comKennedy Capital Management LLC Buys Shares of 60,494 Oruka Therapeutics, Inc. (NASDAQ:ORKA)April 17, 2025 | marketbeat.comFmr LLC Increases Stock Holdings in Oruka Therapeutics, Inc. (NASDAQ:ORKA)April 16, 2025 | marketbeat.comVanguard Group Inc. Acquires 1,572,853 Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA)April 16, 2025 | marketbeat.comWhy Oruka Therapeutics, Inc.’s (ORKA) Stock Is Up 6.65%April 16, 2025 | aaii.comOruka Therapeutics, Inc. (NASDAQ:ORKA) Receives Consensus Rating of "Buy" from AnalystsApril 7, 2025 | marketbeat.comWe're Not Very Worried About Oruka Therapeutics' (NASDAQ:ORKA) Cash Burn RateMarch 8, 2025 | finance.yahoo.comOruka Therapeutics at Risk: Navigating Licensing Challenges and Partner RelianceMarch 8, 2025 | tipranks.comOruka Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides ...March 7, 2025 | bakersfield.comOruka Therapeutics announces preclinical data for ORKA-002March 7, 2025 | markets.businessinsider.comOruka Therapeutics Announces Preclinical Data for ORKA-002 at the 2025 American Academy of Dermatology Annual MeetingMarch 7, 2025 | globenewswire.comOruka Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate UpdateMarch 6, 2025 | globenewswire.comOruka Therapeutics sees $1.41 million in stock purchases by Venrock HealthcareMarch 1, 2025 | investing.comVenrock Healthcare Capital Par Purchases 8,971 Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA) StockFebruary 28, 2025 | insidertrades.comOruka Therapeutics to Present at Multiple March Investor ConferencesFebruary 19, 2025 | globenewswire.comStifel Nicolaus Remains a Buy on Oruka Therapeutics (ORKA)February 10, 2025 | markets.businessinsider.comWhy Oruka Therapeutics, Inc.’s (ORKA) Stock Is Down 12.84%February 8, 2025 | aaii.comWolfe Research Initiates Coverage of Oruka Therapeutics (ORKA) with Outperform RecommendationFebruary 6, 2025 | msn.comOruka Therapeutics inks exclusive license deal with ParagonFebruary 6, 2025 | msn.comOruka Therapeutics initiated with an Outperform at Wolfe ResearchFebruary 3, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAre Tariffs Threatening Disney’s Comeback Story?By Jea Yu | April 9, 2025View Are Tariffs Threatening Disney’s Comeback Story?2 Defensive Sectors to Protect Your Portfolio During a RecessionBy Ryan Hasson | April 7, 2025View 2 Defensive Sectors to Protect Your Portfolio During a RecessionBroadcom’s Apple Relationship: AI Opportunity Meets Tariff RiskBy Leo Miller | April 17, 2025View Broadcom’s Apple Relationship: AI Opportunity Meets Tariff RiskIs Alphabet Misunderstood? Here’s Why the Bulls Are BuyingBy Ryan Hasson | April 21, 2025View Is Alphabet Misunderstood? Here’s Why the Bulls Are BuyingWhy Smart Investors Don’t Panic in Election SeasonBy Sarah Horvath | April 24, 2025View Why Smart Investors Don’t Panic in Election SeasonMGNX, ORKA, ORIC, and CKPT Company DescriptionsCheckpoint Therapeutics NASDAQ:CKPT$4.10 +0.01 (+0.24%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$4.09 -0.01 (-0.15%) As of 04/25/2025 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Checkpoint Therapeutics, Inc., a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors. It is developing Olafertinib, which is in Phase 3 clinical trials for the treatment of adult patients with metastatic non-small cell lung cancer; CK-103 for the treatment of various advanced and metastatic solid tumor cancers; and Anti-Carbonic Anhydrase IX (CAIX) antibody, a product candidate in preclinical trials to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has licensing and collaboration agreements with Adimab, LLC for the development of Cosibelimab; NeuPharma, Inc., to develop and commercialize Olafertinib; and Jubilant Biosys Limited for the development and commercialization of novel compounds that inhibit BET bromodomains. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.MacroGenics NASDAQ:MGNX$1.71 -0.08 (-4.47%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$1.75 +0.04 (+2.34%) As of 04/25/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.ORIC Pharmaceuticals NASDAQ:ORIC$5.10 -0.09 (-1.73%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$5.09 -0.01 (-0.20%) As of 04/25/2025 05:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.Oruka Therapeutics NASDAQ:ORKA$10.09 -0.41 (-3.90%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$10.08 -0.01 (-0.10%) As of 04/25/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 04/21 - 04/25 Bears Can Reap Big Benefits With These 3 Short ETF Bets If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy 3 Stocks To Watch For When Tariffs Subside 3 Boring Stocks Outperforming the Market This Year Short Sellers Gave Up on These 3 Names Recently Churchill Downs Stock: Could Tariff Fears Dampen Derby Gains? Markets Think Robinhood Earnings Could Send the Stock Up Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
